JS 203
Alternative Names: JS-203Latest Information Update: 12 Apr 2023
At a glance
- Originator Shanghai Junshi Biosciences
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma
Most Recent Events
- 13 Feb 2023 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in China (Parenteral) (NCT05618327) (Shanghai Junshi Biosciences pipeline, April 2023)
- 23 Nov 2022 Preclinical trials in Non-Hodgkin's lymphoma in China (Parenteral) before November 2022
- 16 Nov 2022 Shanghai Junshi Biosciences plans a phase I trial for B-cell lymphoma (Second-line therapy or greater, In adults, In the elderly) in China (Parenteral, Injection) in November 2022 (NCT05618327)